Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07014709 (IPMN-GLP1RA) for IPMN, IPMN, Pancreatic, GLP-1, Intraductal Papillary Mucinous Neoplasm of Pancreas, Glucagon-Like Peptide-1 Receptor Agonists is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Impact of GLP-1 Receptor Agonists on Patients With IPMN (IPMN-GLP1RA) 30
Clinical Trial NCT07014709 (IPMN-GLP1RA) is an observational study for IPMN, IPMN, Pancreatic, GLP-1, Intraductal Papillary Mucinous Neoplasm of Pancreas, Glucagon-Like Peptide-1 Receptor Agonists and is currently not yet recruiting. Enrollment is planned to begin on May 31, 2025 and continue until the study accrues 30 participants. Led by Hôpital Fribourgeois, this study is expected to complete by October 31, 2026. The latest data from ClinicalTrials.gov was last updated on June 11, 2025.
Brief Summary
This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy. With the increasing use of GLP-1 RAs for managing diabetes and obesity, concerns about their potential to influence pancreatic conditions, like IPMNs, have emerged. Although GLP-1 RAs are generally safe, their...Show More
Detailed Description
This is a retrospective, multicentric cohort study designed to investigate the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a subtype of pancreatic cystic neoplasms with variable but potentially significant malignant potential. IPMNs are increasingly diagnosed due to advancements in cross-sectional imaging techniques, and their management often inclu...Show More
Official Title
Impact of GLP-1 Receptor Agonists on Patients With Intraductal Papillary Mucinous Neoplasms: A Retrospective Multicentric Cohort Study
Conditions
IPMNIPMN, PancreaticGLP-1Intraductal Papillary Mucinous Neoplasm of PancreasGlucagon-Like Peptide-1 Receptor AgonistsPublications
Scientific articles and research papers published about this clinical trial:Other Study IDs
- IPMN-GLP1RA
NCT ID Number
Start Date (Actual)
2025-05-31
Last Update Posted
2025-06-11
Completion Date (Estimated)
2026-10-31
Enrollment (Estimated)
30
Study Type
Observational
Status
Not yet recruiting
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
Intraductal Papillary Mucinous Neoplasms Patients eligible for this study must have a radiological diagnosis of IPMN | GLP1 receptor agonist Patients must be under GLP1-RA treatment for ether diabetes or obesity |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Radiological changes in pancreatic cyst characteristic as described in the Kyoto 2023 Consensus | Radiological data, including data from MRI scans, will be used to monitor changes in IPMN characteristics. If only CT scans are available, they will also be evaluated, even if this is not the preferred imaging method for IPMN evaluation | during the GLP1 RA treatment |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Incidence of acute pancreatitis | The incidence of acute pancreatitis under GLP1-RA will be evaluated | during the GLP1 RA treatment |
Changes in serum tumor markers, CA19-9 and CEA levels | When already available in routine analyses before and after initiation of GLP-1 RA therapy, tumor markers level will be assessed to detect any changes | during the GLP1 RA treatment |
Changes in Endoscopic ultrasonography (EUS) characteristics | Evaluate the changes of morphological IPMN characteristic in endoscopic ultrasonography (EUS) | during the GLP1 RA treatment |
Progression of IPMNs to high-grade dysplasia or invasive malignancy in histopathological analysis | Evaluate the progression of IPMNs to high-grade dysplasia or invasive malignancy in histopathological analysis | during the GLP1 RA treatment |
Need for surgical intervention | Investigate the need for surgical intervention associated with the introduction of GLP-1 RA treatment | during the GLP1 RA treatment |
Changes in IPMN surveillance protocols | Investigate the need for changes in IPMN surveillance protocols associated with GLP-1 RA use. | during the GLP1 RA treatment |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- > 18 years old
- Radiological diagnosis of IPMN
- Treated with GLP-1 RAs.
- Patients must have provided prior informed consent for the use of their coded clinical data in research.
- radiological diagnosis of IPMN is unclear,
- no documented history of GLP-1 RAs use
- patients did not provide signed informed consent, or have documented refusal for research.
Hôpital Fribourgeois- Insel Gruppe AG, University Hospital Bern
- University Hospital, Geneva
Study Central Contact
Contact: Melissa Lagger, Dipl.med, +41798164051, [email protected]
1 Study Locations in 1 Countries
HFR Hopital fribourgeois, Villars-sur-Glâne, 1752, Switzerland
Melissa Lagger, Contact, +41263062608, [email protected]
Léo Buhler, Prof., Contact, +41263062510, [email protected]
Michel Adamina, Prof, Principal Investigator